Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice

BACKGROUND: Leishmaniasis is a protozoan disease, affecting 12 million people in different regions of the world with a wide spectrum of diseases. Although several chemotherapeutic agents have been used for treating the disease, long-term therapy, limited efficacy and the development of drug-resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Danesh-Bahreini, Mohammad Ali, Shokri, Javad, Samiei, Afshin, Kamali-Sarvestani, Eskandar, Barzegar-Jalali, Mohammad, Mohammadi-Samani, Soliman
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090280/
https://www.ncbi.nlm.nih.gov/pubmed/21589651
http://dx.doi.org/10.2147/IJN.S16805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090280/
https://www.ncbi.nlm.nih.gov/pubmed/21589651
http://dx.doi.org/10.2147/IJN.S16805

Ejemplares similares